204 related articles for article (PubMed ID: 30239425)
1. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
2. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
[TBL] [Abstract][Full Text] [Related]
4. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.
Roskam-Kwint M; Bollen P; Colbers A; Duisenberg-van Essenberg M; Harbers V; Burger D
J Antimicrob Chemother; 2018 Sep; 73(9):2430-2434. PubMed ID: 29796595
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM; Kiser JJ; Ziemba L; Ward S; Rani Y; Cressey TR; Masheto GR; Cassim H; Deville JG; Ponatshego PL; Patel F; Aurpibul L; Barnabas SL; Mustich I; Coletti A; Heckman B; Krotje C; Lojacono M; Yin DE; Townley E; Moye J; Majji S; Acosta EP; Ryan K; Chandasana H; Brothers CH; Buchanan AM; Rabie H; Flynn PM;
Lancet HIV; 2023 Aug; 10(8):e506-e517. PubMed ID: 37541705
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
[TBL] [Abstract][Full Text] [Related]
7. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828
[TBL] [Abstract][Full Text] [Related]
8. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
[TBL] [Abstract][Full Text] [Related]
9. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
11. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Allavena C; Volteau C; André-Garnier E; Guimard T; Hall N; Khatchatourian L; Morrier M; Billaud E; Rodallec A; Reliquet V; Jovelin T; Le Guen L; Perré P; Grégoire M; Raffi F
Med Mal Infect; 2019 Oct; 49(7):505-510. PubMed ID: 30583867
[TBL] [Abstract][Full Text] [Related]
12. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
13. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
[TBL] [Abstract][Full Text] [Related]
14. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
16. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
van Dam PM; van Geffen MW; Havenith TR; Posthouwer D
Antivir Ther; 2018; 23(6):549-552. PubMed ID: 29533918
[TBL] [Abstract][Full Text] [Related]
17. Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Baldin G; Ciccullo A; Rusconi S; Madeddu G; Sterrantino G; Freedman A; Giacometti A; Celani L; Latini A; Rossetti B; Cossu MV; Giacomelli A; Lagi F; Capetti A; Di Giambenedetto S
Infez Med; 2019 Dec; 27(4):410-414. PubMed ID: 31846991
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
[TBL] [Abstract][Full Text] [Related]
19. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
20. Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Comi L; Maggiolo F
Expert Opin Pharmacother; 2016 Oct; 17(15):2097-106. PubMed ID: 27616133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
